Skip to main content
SpringerLink
Log in

Palliative Treatments

  • Chapter
Treatment of Peritoneal Surface Malignancies

Part of the book series: Updates in Surgery ((UPDATESSURG))

Abstract

During the last two decades, cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy (CRS plus HIPEC) has received increasing attention as a promising treatment for peritoneal carcinomatosis (PC) from several primary tumor types. However, many patients with advanced disease have no indications to be treated either by this procedure or by any other systemic therapy. Chronic pain, development of malignant ascites (MA), and bowel obstruction are often reported by the majority of those patients, with detrimental physiological and psychological status affecting quality of life (QoL) and leading to very poor prognosis [1–6]. Even if still controversial, CRS plus HIPEC may play an important role in palliative treatment, especially when associated with a less invasive approach to obtain the best results with limited morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Feuer DJ, Broadley KE, Shepherd JH et al (2000) Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev CD002764

    Google Scholar 

  2. Chakraborty A, Selby D, Gardiner K et al (2011) Malignant bowel obstruction: natural history of a heterogeneous patient population followed prospectively over two years. J Pain Symptom Manage. 41:412–420

    Article  PubMed  Google Scholar 

  3. Ripamonti C, Mercadante S (2005) Pathophysiology and management of malignant bowel obstruction. In: Doyle D, Hanks GW, McDonald N, Cherny N, eds. Oxford textbook of palliative medicine, 3rd edn., Oxford University Press, New York, pp 496–506

    Google Scholar 

  4. Feuer DJ, Broadley KE (1999) Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol 10:1035–1041

    Article  CAS  PubMed  Google Scholar 

  5. Feuer DJ, Broadley KE, Shepherd JH et al (1999) Systematic review of surgery in malignant bowel obstruction in advanced gynecological and gastrointestinal cancer. The Systematic Review Steering Committee. Gynecol Oncol 75:313–322

    Article  CAS  PubMed  Google Scholar 

  6. McQuellon RP, Loggie BW, Fleming RA et al (2001) Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 27:65–73

    Article  CAS  PubMed  Google Scholar 

  7. Chung M, Kozuch P (2008) Treatment of malignant ascites. Curr Treat Options Oncol 9:215–233

    Article  PubMed  Google Scholar 

  8. Tamsma JT, Keizer HJ, Meinders AE (2001) Pathogenesis of malignant ascites: Starling’s law of capillary hemodinamics revisited. Ann Oncol 12:1353–1357

    Article  CAS  PubMed  Google Scholar 

  9. Runyon BA (1994) Care of patients with ascites. N Engl J Med 330:337–342

    Article  CAS  PubMed  Google Scholar 

  10. Mackey JR, Venner PM (1996) Malignant ascites: demographics, therapeutic efficacy and predictors of survival Can J Oncol 6:474–480

    CAS  PubMed  Google Scholar 

  11. Ayantunde AA, Parsons SL (2007) Pattern and prognostic factors in patietns with malignant ascites: a retrospective study. Ann Oncol 18:945–949

    Article  CAS  PubMed  Google Scholar 

  12. Garrison RN, Kaelin LD, Galloway RH et al (1986) Malignant ascites. Clinical and experimental observations. Ann Surg 203:644–651

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  13. Parsons SL, Watson SA, Steele RJ (1996) Malignant ascites. Br J Surg 83:6–14

    Article  CAS  PubMed  Google Scholar 

  14. Sugarbaker PH, Welch LS, Mohamed F et al (2003) A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12:605–621

    Article  PubMed  Google Scholar 

  15. Knutsen A, Sielaff TD, Greeno E et al (2006) Staged laparoscopic infusion of hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. J Gastrointestinal Surg 10:1038–1043

    Article  Google Scholar 

  16. Garofalo A, Valle M, Garcia J et al (2006) Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites. Eur J Surg Oncol 32:682–685

    Article  CAS  PubMed  Google Scholar 

  17. Sommariva A, Zagonel V, Rossi CR (2012) The role of laproscopy in peritoneal surface malignancies selected for hyperthermic intraperitnoeal chemotherapy (HIPEC). Ann Surg Oncol 19:3737–3744

    Article  PubMed  Google Scholar 

  18. Sangisetty SL, Miner TJ (2012) Malignant ascites: a review of prognostic factors, pathophysiology and therapeutic measures. World J Gastrointest Surg 4:87–95

    Article  PubMed Central  PubMed  Google Scholar 

  19. Lee CW, Bociek G, Faught W (1998) Asurvey of practice in management of malignant ascites. J Pain Symptom Manage 16:96–101

    Article  CAS  PubMed  Google Scholar 

  20. Becker G, Galandi D, Blum HE (2006) Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 42:589–597

    Article  PubMed  Google Scholar 

  21. Smith EM, Jayson GC (2003) The current and future management of malignant ascites. Clin Oncol 15:59–72

    Article  CAS  Google Scholar 

  22. Adam RA, Adam YG (2004) Malignant ascites: past, present and future. J Am Coll Surg 198:999–1011

    Article  PubMed  Google Scholar 

  23. Heiss MM, Murawa P, Koralewski P et al (2010) The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial Int J Cancer 127:2209–2221

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Sommariva A, Pilati P, Rossi CR (2012) Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies: current treatment and results. Cancer Treat Rev 38:258–268

    Article  PubMed  Google Scholar 

  25. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Esquivel J (2009) Technology of hyperthermic intraperitoneal chemotherapy in the United States, Europe, China, Japan, and Korea. Cancer J 15:249–254

    Article  PubMed  Google Scholar 

  27. Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242

    Article  PubMed  Google Scholar 

  28. Cao C, Yan TD, Black D (2009) A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 16:2152–2165

    Article  PubMed  Google Scholar 

  29. Chua TC, Robertson G, Liauw W et al (2009) Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol 135:1637–1645

    Article  PubMed  Google Scholar 

  30. Yan TD, Balck D, Sugarbaker PH et al (2007) A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol 14:2702–2713

    Article  PubMed  Google Scholar 

  31. Verwaal VJ, Van Ruth S, De Bree E et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743

    Article  PubMed  Google Scholar 

  32. Sugarbaker PH, Cunliffe WJ, Belliveau J et al (1989) Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 16:83–97

    CAS  PubMed  Google Scholar 

  33. Chang E, Alexandr HL, Libutti SK et al (2001) Laparoscopic continuous hypertermic peritoneal perfusion. J Am Coll Surg 193:225–229

    Article  CAS  PubMed  Google Scholar 

  34. Facchiano, Scaringi S, Kianmanesh R et al (2008) Laparoscopic hypertermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer. Eur J Surg Oncol 34:154–158

    Article  CAS  PubMed  Google Scholar 

  35. Patriti A, Cavazzoni E, Graziosi L et al (2008) Successful palliation of malignant ascites from peritonela mesothelioma by laparoscopi intraperitoneal hypertemric chemotherapy. Surg Laparosc Endosc Percutaneous Tech 18:426–428

    Article  Google Scholar 

  36. Valle M, Van der Speeten K, Garofalo A (2009) laparoscopic hypertermic intraperitoneal peorperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol 100:331–334

    Article  CAS  PubMed  Google Scholar 

  37. Ba MC, Cui SZ, Lin SQ et al (2010) Chemotherapy with laparoscope-assisted continuous circulatory Hyperthermic intraperitoneal perfusion for malignant ascites. World J Gastroenterol 16:1901–1907

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Graziosi L, Bugiantella W, Cavazzoni E et al (2009) Laparoscopic intraperitoneal hyperthermic perfusion in palliation of malignant ascites; a case report. G Chir 30:237–9

    CAS  PubMed  Google Scholar 

  39. De Mestier L, Volet J, Scaglia E et al (2012) Palliative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy Effective in Patients with Malignant Hemorrhagic Ascites? Case Rep Gastroenterol 6:166–170

    Article  PubMed Central  PubMed  Google Scholar 

  40. Randle RW, Swett KR, Swords DS et al (2013) Efficacy of Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in the Management of Malignant Ascites. Ann Surg Oncol 21: 1474–1479

    Article  PubMed Central  PubMed  Google Scholar 

  41. Valle M, Federici O, Garofalo A (2012) Patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and role of laparoscopy in diagnosis, staging and treatment. Surg Oncol Clin N Am 21:515–531

    Article  PubMed  Google Scholar 

  42. Ozols RF, Young RC, Speyer JL et al (1982) Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 42:4265–4269

    CAS  PubMed  Google Scholar 

  43. Sugarbaker PH (1996) Early post-operative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma. Cancer Treat Res 81:7–14

    Article  CAS  PubMed  Google Scholar 

  44. Hagiwara A, Takahashi T, Sawai K et al (1993) Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res 53:687–692

    CAS  PubMed  Google Scholar 

  45. Kobold S, Hegewish-Becker S, Oechsle K et al (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? The Oncologist 14:1242–1251

    Article  CAS  PubMed  Google Scholar 

  46. Hamilton CA, Maxwell GL, Chernofsky MR et al (2008) Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111:530–532

    Article  CAS  PubMed  Google Scholar 

  47. Ströhlein MA, Siegel R, Jäger M et al (2009) Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 28:18

    Article  PubMed Central  PubMed  Google Scholar 

  48. Numnum TM, Rocconi RP, Whitworth J et al (2006) The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. Gynecol Oncol 102:425–428

    Article  CAS  PubMed  Google Scholar 

  49. Tempfer CB, Celik I, Solass W et al (2014) Activity of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol 132:307–311

    Article  CAS  PubMed  Google Scholar 

  50. Solass W, Kerb R, Muerdter T et al (2014) Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21:553–559

    Article  PubMed Central  PubMed  Google Scholar 

  51. Blanco A, Giger-Pabst U, Solass W et al (2013) Renal and hepatic toxicity after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 20:2311–6

    Article  PubMed Central  PubMed  Google Scholar 

  52. Laval G, Marcelin-Benazech B, Guirimand F et al (2014) Recommendations for bowel obstruciotn with peritnoneal carcinomatosis. J pain symptom manage May 4. pii: S0885-3924(14)00232-2

    Google Scholar 

  53. Baines MJ (2000) Symptom control in advanced gastrointestinal cancer. Eur J Gastroenterol Hepatol 12:375–379

    Article  CAS  PubMed  Google Scholar 

  54. Silva AC, Pimenta M, Guimares LS (2009) Small bowel obstruction: what to look for? Radiographics 29:423–439

    Article  PubMed  Google Scholar 

  55. Osteen RT, Guyton S, Steele G et al (1980) Malignant intestinal obstruction. Surgery 87:611–615

    CAS  PubMed  Google Scholar 

  56. Woolfson RG, Jennings K, Whalen GF (1997) Management of bowel obstruction in patients with abdominal cancer. Arch Surg 132:1093–1097

    Article  CAS  PubMed  Google Scholar 

  57. Helyer L, Easson AM (2008) Surgical approaches to malignant bowel obstruction. J Support Oncol 6:105–113

    PubMed  Google Scholar 

  58. Mendelsohn RB, Gerdes H, Markowitz AJ et al (2011) Carcinomatosis is not a contraindication to enteral stenting in selected patients with malignant gastric outlet obstruction. Gastrointest Endosc 3:1135–1140

    Article  Google Scholar 

  59. Manes G, De Bellis M, Fuccio L et al (2011) Endoscopic palliation in patients with incurable malignant colorectal by means of self-expanding metal stents. Arch Surg 146:1157–1162

    Article  PubMed  Google Scholar 

  60. McCarthy JD (1986) A strategy for intestinal obstruction of peritoneal carcinomatosis. Arch Surg 121:1081–1082

    Article  CAS  PubMed  Google Scholar 

  61. Turnbull AD, Guerra J, Starnes HF (1989) Results of surgery for obstructing carcinomatosis of gastrointestinal pancreatic or biliary origin. J Clin Oncol 7:381–386

    CAS  PubMed  Google Scholar 

  62. Lau PW, Lorentz TG (1993) Results of surgery for malignant bowel obstruction in advanced unresectable recurrent colorectal cancer. Dis Colon Rectum 36:61–64

    Article  CAS  PubMed  Google Scholar 

  63. Lund B, Hansen M, Lundvall F et al (1989) Intestinal obstruction in patients with advanced carcinoma of the ovaries treated with combination chemotherapy. Gynecol Obstet 169:213–218

    CAS  Google Scholar 

  64. Jong P, Sturgeon J, Jamieson CG (1995) Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg 38:454–457

    CAS  PubMed  Google Scholar 

  65. Mangili G, Aletti G, Firgerio L et al (2005) Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer 15:830–835

    Article  CAS  PubMed  Google Scholar 

  66. Chi DS, Phaeton R, Miner TJ et al (2009) A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist 14:835–839

    Article  PubMed  Google Scholar 

  67. Blair SL, Chu DZJ, Schwartz RE (2001) Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynaecological cancer. Ann Surg Oncol 8:632–637

    Article  CAS  PubMed  Google Scholar 

  68. Abbas SM, Merrie AE (2006) Palliative small bowel surgery in patients with history of malignancy. Int J Cancer Res 2:42–46

    Article  Google Scholar 

  69. Kolomainen DF, Daponte A, Barton DPJ et al (2012) Outcomes of surgical management of bowel obstruction in relapsed epithelial ovarian cancer (EOC). Gynecol Oncol 125:31–36

    Article  CAS  PubMed  Google Scholar 

  70. Olson TJP, Pinkerton C, Brasel K et al (2014) Palliative surgery for malignant bowel obstruction from carcinomatosis. A systematic review. JAMA surg 149:383–392

    Article  Google Scholar 

  71. Van Ooijen B, Van Der Burg MEL et al (1993) Planting AS et al Surgical treatment or gastric drainage only for intestinal obstruction in patients with carcinoma of the ovary or peritoneal carcinomatosis of other origin. Surg Gynecol Obstet 176:469–474

    PubMed  Google Scholar 

  72. Legendre H, Vanhuyse F, Caroli-Bosc FX, Pector JC (2001) Survival and quality of life after palliative surgery for neoplastic gastrointestinal obstruction. Eur J Surg Oncol 27:364–367

    Article  CAS  PubMed  Google Scholar 

  73. Piver MS, Barlow JJ, Lele SB et al (1982) Survival after ovarian cancer induced intestinal obstruction. Gynecol Oncol 13:44–49

    Article  CAS  PubMed  Google Scholar 

  74. Rubin SC, Hoskins WJ, Benjamin I et al (1989) Palliative surgery for intestinal obstruction in advanced ovarian cancer. Gynecol Oncol 34:16–19

    Article  CAS  PubMed  Google Scholar 

  75. Bais JMJ, Schiltuis MS, Slors JFM et al (1995) Intestinal obstruction in patients with advanced ovarian cancer. Int J Gynecol Cancer 5:346–350

    Article  PubMed  Google Scholar 

  76. Pothuri B, Vaidya A, Aghajanian C et al (2003) Palliative surgery for bowel obstruction n recurrent ovarian cancer: an updated series. Gynecol Oncol 89:306–313

    Article  PubMed  Google Scholar 

  77. Kim K, Kang SB, Kim MJ et al (2009) Factors associated with successful palliation and improved survival in patients with malignant bowel obstruction caused by ovarian cancer. J Women Med 2:54–58

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

    Simone Sibio

Authors
  1. Simone Sibio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Maher Fouad Atta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniele Biacchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Enzo Naticchioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maurizio Cardi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simone Sibio .

Editor information

Editors and Affiliations

  1. Department of Surgery “Pietro Valdoni”, Sapienza University of Rome, Rome, Italy

    Angelo Di Giorgio

  2. Department of Medical, Surgical, and Neurological Sciences, University of Siena, Siena, Italy

    Enrico Pinto

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Italia

About this chapter

Cite this chapter

Sibio, S., Atta, J.M.F., Biacchi, D., Naticchioni, E., Cardi, M. (2015). Palliative Treatments. In: Di Giorgio, A., Pinto, E. (eds) Treatment of Peritoneal Surface Malignancies. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5711-1_23

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5711-1_23

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5710-4

  • Online ISBN: 978-88-470-5711-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation